


Appl. No. 10/632,187
 Amdt. Dated May 3, 2005
 Reply to Non-Final Office Action of November 3, 2004
 Page 2 of 13


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (amended): The method of using of alkylphosphocholines of the general Formula I ~~and~~ or
 II:



Formula I



Formula II

in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;

x is O, S, NH;

R is hydrogen, a linear or branched C₁ to C₂₀ alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C₁ to C₆ alkoxy, amino, mono-(C₁ to C₄) alkylamino or di-(C₁ to C₄) alkylamino groups;

R₁, R₂, R₃ independently of one another represent hydrogen, a linear or branched (C₁ to C₆) alkyl group, preferably methyl and ethyl, a (C₃ to C₆) cycloalkyl group ~~(C₃ to C₇) cycloalkyl group~~, which may be unsubstituted or optionally substituted at the same

Appl. No. 10/632,187


Amdt. Dated May 3, 2005

Reply to Non-Final Office Action of November 3, 2004

Page 3 of 13

or different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C₁ to C₆ alkoxy, amino, mono-(C₁ to C₄) alkylamino or di-(C₁ to C₄) alkylamino groups and pharmaceutically acceptable salts and prodrugs thereof; for the manufacture of a drug product for the treatment of benign and malignant oncose before and/or during treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabine ~~and pharmaceutically acceptable salts and prodrugs thereof~~.

Claim 2 (amended): The method of using of compound having the structure of Formula I:



Formula I

where, independently of one another,

n is the integer 1 or 2;

m is the integer 1;

x is O;


R is H or a straight-chain or branched (C₁-C₁₇)-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

R₁, R₂, R₃ are, independently of one another, H or a straight-chain or branched (C₁-C₇)-alkyl group, preferably methyl and ethyl, a (C₃-C₇)-cycloalkyl group;

Appl. No. 10/632,187
 Amdt. Dated May 3, 2005
 Reply to Non-Final Office Action of November 3, 2004
 Page 4 of 13

for the manufacture of a drug product for the treatment of benign and malignant oncose
 before and/or during treatment with an approved ~~antitumor medicament~~ antitumor or
substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin,
doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide,
teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine
and cytarabin.

Claim 3 (amended): The method of using of alkylphosphocholines of the general Formula II as
 claimed in claim 1



Formula II

where, independently of one another,

m, p are the integer 1;

n, z are the integer 2;

x is O;

R is H or a straight-chain or branched (C₁-C₁₇)-alkyl group which may be saturated or
 unsaturated with one to three double and/or triple bonds;

R₁, R₂, R₃ are, independently of one another, H or a straight-chain or branched (C₁-C₇)-alkyl
 group, preferably methyl and ethyl, a (C₃-C₇)-cycloalkyl group;

Appl. No. 10/632,187
Amdt. Dated May 3, 2005
Reply to Non-Final Office Action of November 3, 2004
Page 5 of 13

for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 4 (amended): The method of using of octadecyl 1,1-dimethylpiperidinium-4-yl phosphat as claimed in claim 1 for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 5 (amended): The method of using of alkylphosphocholines of the general formula Formula I and or II as claimed in ~~claims 1 to 4, where as in any one of the preceding claims, in which~~ the approved antitumor medicaments may be alkylating agents, antimetabolites, plant alkaloids, platinum compounds, tumor antibiotics and agonists or antagonists of natural hormones.

Claim 6 (original): The method of using as claimed in claim 5, wherein the antitumor medicaments may be cisplatin, cyclophosphamide or Adriamycin.

Claim 7 (amended): The method of using of alkylphosphocholines of the general Formula I ~~and or~~ or II as claimed in ~~claims 1 to 4, where as in any one of claims 1, 2, 3, and 4, in which~~ the approved

Appl. No. 10/632,187
Amdt. Dated May 3, 2005
Reply to Non-Final Office Action of November 3, 2004
Page 6 of 13

antitumor medicaments may be inhibitors of signal transduction in the form of high and low molecular weight inhibitors of receptor and/or cytosolic kinases.

Claim 8 (original): The method of using as claimed in claim 7, where the inhibitors may be monoclonal antibodies or heterocyclic compounds.

Claim 9 (amended): The method of using of alkylphosphocholines of the general Formula I and or II as claimed in ~~claims 1 to 8~~ any one of the preceding claims in a therapeutic dose which is effective for the treatment before and/or during the treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 10 (amended): The method of using of alkylphosphocholines of the general formula Formula I and or II as claimed in ~~claims 1 to 9~~ any one of the preceding claims, where the approved antitumor medicament is a combination of various cytostatics.

Claim 11 (amended): The method of using of alkylphosphocholines of the ~~formula~~ Formula I and or II as claimed in ~~claims 1 to 4~~ any one of claims 1, 2, 3, and 4 for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during the treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil,

Appl. No. 10/632,187
Amdt. Dated May 3, 2005
Reply to Non-Final Office Action of November 3, 2004
Page 7 of 13

fludarabin, gemcitabin and cytarabin, wherein the drug product comprises the customary pharmaceutical carriers, excipients and/or diluents in addition to the alkylphosphocholine of the Formula I and or II.

Claim 12 (amended): A drug product comprising at least one alkylphosphocholine of the general Formula I ~~and or II~~ as in claim 1 and, where appropriate, carriers and/or excipients for use in the treatment of benign and malignant oncoses before and/or during the treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatin, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.